Adjuvant and Salvage Radiotherapy after Prostatectomy

ASTRO/AUA Guideline Amendment 2018-2019

Thomas M. Pisansky, Ian M. Thompson, Richard K Valicenti, Anthony V. D'Amico, Shalini Selvarajah

Research output: Contribution to journalArticle

Abstract

PURPOSE: The purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians. MATERIALS AND METHODS: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published from January 1990 through December 2017. Two new key questions were added. One on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation post-radical prostatectomy. RESULTS: A new statement on the use of hormone therapy with salvage radiotherapy after radical prostatectomy was added and long-term data was used to update an existing statement on adjuvant radiotherapy. The balance of the guideline statements were re-affirmed and references were added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases was found. CONCLUSIONS: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage radiotherapy. The clinician should discuss possible short- and long-term side effects with the patient as well as the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multi-disciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.

Original languageEnglish (US)
Pages (from-to)533-538
Number of pages6
JournalThe Journal of urology
Volume202
Issue number3
DOIs
StatePublished - Sep 1 2019

Fingerprint

Adjuvant Radiotherapy
Prostatectomy
Guidelines
Hormones
Radiotherapy
Neoplasm Metastasis
Salvage Therapy
Therapeutics
Quality of Life
Radiation
Recurrence

Keywords

  • prostatic neoplasms
  • radiation
  • salvage therapy

ASJC Scopus subject areas

  • Urology

Cite this

Adjuvant and Salvage Radiotherapy after Prostatectomy : ASTRO/AUA Guideline Amendment 2018-2019. / Pisansky, Thomas M.; Thompson, Ian M.; Valicenti, Richard K; D'Amico, Anthony V.; Selvarajah, Shalini.

In: The Journal of urology, Vol. 202, No. 3, 01.09.2019, p. 533-538.

Research output: Contribution to journalArticle

Pisansky, Thomas M. ; Thompson, Ian M. ; Valicenti, Richard K ; D'Amico, Anthony V. ; Selvarajah, Shalini. / Adjuvant and Salvage Radiotherapy after Prostatectomy : ASTRO/AUA Guideline Amendment 2018-2019. In: The Journal of urology. 2019 ; Vol. 202, No. 3. pp. 533-538.
@article{f3d67358038b49e3acdebab6b80bc73a,
title = "Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019",
abstract = "PURPOSE: The purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians. MATERIALS AND METHODS: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published from January 1990 through December 2017. Two new key questions were added. One on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation post-radical prostatectomy. RESULTS: A new statement on the use of hormone therapy with salvage radiotherapy after radical prostatectomy was added and long-term data was used to update an existing statement on adjuvant radiotherapy. The balance of the guideline statements were re-affirmed and references were added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases was found. CONCLUSIONS: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage radiotherapy. The clinician should discuss possible short- and long-term side effects with the patient as well as the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multi-disciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.",
keywords = "prostatic neoplasms, radiation, salvage therapy",
author = "Pisansky, {Thomas M.} and Thompson, {Ian M.} and Valicenti, {Richard K} and D'Amico, {Anthony V.} and Shalini Selvarajah",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/JU.0000000000000295",
language = "English (US)",
volume = "202",
pages = "533--538",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Adjuvant and Salvage Radiotherapy after Prostatectomy

T2 - ASTRO/AUA Guideline Amendment 2018-2019

AU - Pisansky, Thomas M.

AU - Thompson, Ian M.

AU - Valicenti, Richard K

AU - D'Amico, Anthony V.

AU - Selvarajah, Shalini

PY - 2019/9/1

Y1 - 2019/9/1

N2 - PURPOSE: The purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians. MATERIALS AND METHODS: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published from January 1990 through December 2017. Two new key questions were added. One on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation post-radical prostatectomy. RESULTS: A new statement on the use of hormone therapy with salvage radiotherapy after radical prostatectomy was added and long-term data was used to update an existing statement on adjuvant radiotherapy. The balance of the guideline statements were re-affirmed and references were added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases was found. CONCLUSIONS: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage radiotherapy. The clinician should discuss possible short- and long-term side effects with the patient as well as the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multi-disciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.

AB - PURPOSE: The purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians. MATERIALS AND METHODS: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published from January 1990 through December 2017. Two new key questions were added. One on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation post-radical prostatectomy. RESULTS: A new statement on the use of hormone therapy with salvage radiotherapy after radical prostatectomy was added and long-term data was used to update an existing statement on adjuvant radiotherapy. The balance of the guideline statements were re-affirmed and references were added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases was found. CONCLUSIONS: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage radiotherapy. The clinician should discuss possible short- and long-term side effects with the patient as well as the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multi-disciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.

KW - prostatic neoplasms

KW - radiation

KW - salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=85071349491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071349491&partnerID=8YFLogxK

U2 - 10.1097/JU.0000000000000295

DO - 10.1097/JU.0000000000000295

M3 - Article

VL - 202

SP - 533

EP - 538

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -